These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Critical role of toll-like receptors and nucleotide oligomerisation domain in the regulation of health and disease. Mitchell JA, Paul-Clark MJ, Clarke GW, McMaster SK, Cartwright N. J Endocrinol; 2007 Jun; 193(3):323-30. PubMed ID: 17535871 [Abstract] [Full Text] [Related]
7. [Toll-like receptors: recognition receptors of the innate immune system and target structures for therapeutical intervention]. Kabelitz D. Med Monatsschr Pharm; 2012 Jul; 35(7):238-44. PubMed ID: 22852274 [Abstract] [Full Text] [Related]
8. Radiation therapy and Toll-like receptor signaling: implications for the treatment of cancer. Roses RE, Xu M, Koski GK, Czerniecki BJ. Oncogene; 2008 Jan 07; 27(2):200-7. PubMed ID: 18176601 [Abstract] [Full Text] [Related]
9. Therapeutic applications of nucleic acids as ligands for Toll-like receptors. Panter G, Kuznik A, Jerala R. Curr Opin Mol Ther; 2009 Apr 07; 11(2):133-45. PubMed ID: 19330719 [Abstract] [Full Text] [Related]
10. Toll-like receptor and RIG-I-like receptor signaling. Kawai T, Akira S. Ann N Y Acad Sci; 2008 Nov 07; 1143():1-20. PubMed ID: 19076341 [Abstract] [Full Text] [Related]
16. Regulation of TLR expression, a new perspective for the role of VIP in immunity. Gomariz RP, Arranz A, Juarranz Y, Gutierrez-Cañas I, Garcia-Gomez M, Leceta J, Martínez C. Peptides; 2007 Sep 15; 28(9):1825-32. PubMed ID: 17706836 [Abstract] [Full Text] [Related]